Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;4(6):971-975.
doi: 10.3892/mco.2016.835. Epub 2016 Mar 30.

Positive cyclin T expression as a favorable prognostic factor in treating gastric gastrointestinal stromal tumors

Lien-Fu Lin  1 , Jong-Shiaw Jin  2 , Jui-Chang Chen  3 , Chia-Chi Huang  4 , Jeng-Horng Sheu  3 , Wenlung Chen  3 , Tang-Yi Tsao  2 , Chih-Wei Hsu  5
Affiliations

Positive cyclin T expression as a favorable prognostic factor in treating gastric gastrointestinal stromal tumors

Lien-Fu Lin et al. Mol Clin Oncol. 2016 Jun.

Abstract

Positive transcriptional elongation factor b (P-TEFb) contains the catalytic subunit cyclin-dependent kinase 9 (Cdk9) and the regulatory subunit cyclin T. Cyclin T1 and Cdk9 are the key factors of the PTEFb pathways and are overexpressed in the human head and neck carcinoma cell line. However, there have been limited studies regarding the role of cyclin T1 and Cdk9 in gastric gastrointestinal stromal tumors (GISTs). The aim of the present study was to assess the association between cyclin T1 and Cdk9 and their clinical significance in gastric GISTs. A total of 30 gastric GIST patients who underwent either laparoscopic or laparotomic partial gastrectomy were enrolled in the study. The surgical tissue slides were stained with Cdk9 and cyclin T1 antibodies, and the immunohistochemistry scores and disease-free survival (DFS) were analyzed. Ten patients were cyclin T1-positive, and 20 were negative. All 11 patients with recurrent tumors or distant metastases were cyclin T1-negative patients. Old age, large tumor size, a high Ki67 IHC staining score, high mitotic count and negative cyclin T1 staining revealed a worse clinical outcome in univariate analysis. By contrast, the Cdk9 score was not associated with clinical parameters. The Kaplan-Meier survival curve illustrated that the DFS rate of the patients with negative cyclin T1 staining was significantly lower than that of the patients with positive cyclin T1 staining. Positive expression of cyclin T1 was a good prognostic factor in patients with gastric GISTs.

Keywords: cyclin T1; cyclin-dependent kinase 9; disease-free survival; gastric gastrointestinal stromal tumor.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Positive cyclin T1 staining.
Figure 2.
Figure 2.
Kaplan-Meier survival curve of patients with gastrointestinal stromal tumors with negative or positive cyclin T1 staining. Patients with positive staining for cyclin T1 (n=30) showed a significantly good disease-free survival rate (P=0.031).
See this image and copyright information in PMC

References

    1. Scarpa M, Bertin M, Ruffolo C, Polese L, D'Amico DF, Angriman I. A systemic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol. 2008;98:384–392. doi: 10.1002/jso.21120. - DOI - PubMed
    1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: Recent advances in understanding of their biology. Hum Pathol. 1999;30:1213–1220. doi: 10.1016/S0046-8177(99)90040-0. - DOI - PubMed
    1. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Int J Surg pathol. 2002;10:81–99. doi: 10.1177/106689690201000201. - DOI - PubMed
    1. Huang HY, Li CF, Huang WW, Hu TH, Lin CN, Uen YH, Hsiung CY, Lu D. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: A subdivision of the original high-risk group on the basis of outcome. Surgery. 2007;141:748–756. doi: 10.1016/j.surg.2007.01.024. - DOI - PubMed
    1. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, et al. NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl 2):S1–S41. - PMC - PubMed